IP Verse

Preparation Containing Tetracyclic Compound At High Dose - EP3135287

The patent EP3135287 was granted to Chugai Seiyaku Kabushiki Kaisha on Nov 20, 2024. The application was originally filed on Apr 24, 2015 under application number EP15783124A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3135287

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP15783124A
Filing Date
Apr 24, 2015
Status
Granted And Under Opposition
Oct 18, 2024
Grant Date
Nov 20, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ELKINGTON AND FIFEAug 20, 2025ADMISSIBLE
MANSKEAug 20, 2025ADMISSIBLE
TEVA PHARMACEUTICALSAug 19, 2025ADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTJP4918630B
INTERNATIONAL-SEARCH-REPORTJPH02223522
INTERNATIONAL-SEARCH-REPORTJPH09202728
INTERNATIONAL-SEARCH-REPORTWO2012043709
OPPOSITIONEP2441753
OPPOSITIONEP2606886
SEARCHEP2606886

Non-Patent Literature (NPL) Citations (19) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Annette Bauer-Brandl; Wolfgang A. Ritschel, "2.3.5 Sprengmittel oder Zerfallsbeschleuniger", Annette Bauer-Brandl; Wolfgang A. Ritschel, Annette Bauer-Brandl, Wolfgang A. Ritschel, Die Tablette, Cantor Verlag, (20120101), pages 142 - 164, ISBN 978-3-87193-407-0, XP009563114-
OPPOSITION- Anonymous, " ALECENSA ® (alectinib) capsules, for oral use - HIGHLIGHTS OF PRESCRIBING INFORMATION ", FDA, (20151201), FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf, XP093307641-
OPPOSITION- Anonymous, "An Anti-Cancer Agent, ALK Inhibitor "Alecensa ® ," Approved for the Treatment of ALK Fusion Gene Positive Unresectable, Recurrent / Advanced Non-Small Cell Lung Cancer", CHUGAI, (20140704), CHUGAI, URL: https://www.chugai-pharm.co.jp/news/cont_file_dl.php?f=140704eAlecensa_Aproval.pdf&src=[%0],[%1]&rep=130,242, XP093307628-
OPPOSITION- Anonymous, "Innovation beyond Imagination", Chugai, Annual Report 2014, (20141231), Chugai, Annual Report 2014 , URL: https://www.chugai-pharm.co.jp/english/ir/reports_downloads/annual_reports/files/eAR2014_12_00.pdf, XP093307633-
OPPOSITION- Anonymous, "Japan erteilt als erstes Land die Zulassung für Alectinib bei fortgeschrittenem Lungenkrebs", Krebs-Nachrichten Pharma, (20140705), Krebs-Nachrichten Pharma , URL: https://www.krebs-nachrichten.de/pharma-details/japan-erteilt-als-erstes-land-die-zulassung-fuer-alectinib-bei-fortgeschrittenem-lungenkrebs.html, XP093307631-
OPPOSITION- Anonymous, "Pharmaceuticals and Medical Devices Safety Information (No.320)", Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Japan, (20150101), Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Japan, URL: https://www.pmda.go.jp/files/000203635.pdf, XP093307636-
OPPOSITION- Anonymus, "Dosage form design and manufacture", Pharmaceutics: The Science of Dosage Form Design, Churchill Livingstone, (20020101), pages 404 - 408, Pharmaceutics: The Science of Dosage Form Design, (20200303), XP055673015-
OPPOSITION- Ashford M, "Bioavailability - Physicochemical and dosage form factors", Ashford M, AULTON M.E. (ED.).2, PHARMACEUTICS. THE SCIENCE OF DOSAGE FORM DESIGN ED. 2, UK, CHURCHILL LIVIGSTONE , (20020101), pages 234 - 252, 027702, ISBN 978-0-443-05517-1, XP007914455-
OPPOSITION- BRIAN JONES, "29 Hard gelatin capsules", Pharmaceutics: The Science of Dosage Form Design, 2nd Edition, CHURCHILL LIVINGSTONE, (20020101), pages 449 - 460, ISBN 0-443-10107-8, XP009559174-
OPPOSITION- D10 - Pressemeldung Chugai Pharmaceuticals Ltd. über den Start der Vermarktung von “Alecensa®” in Japan (no date found)-
OPPOSITION- D9 - Review Report der Pharmaceuticals and Medical Devices Agency, JP, vom10. Juni 2014-
OPPOSITION- Hutchison, Josephine Ferdinando, "Soft gelatin capsules", Pharmaceutics. The Science of Dosage Form Design, (20010101), pages 461 - 472, XP055790713-
OPPOSITION- JC Hooton, "Carboxymethylcellulose Calcium", JC Hooton, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090203), pages 117 - 118, ISBN 978-0-85369-792-3, XP009563125-
OPPOSITION- Malcolm Summers, Michael Aulton, "25 Granulation", Malcolm Summers, Michael Aulton, Michael E. Aulton, Pharmaceutics THE SCIENCE OF DOSAGE FORM DESIGN; 2nd Edition, Churchill Livingstone, (20020101), pages 364 - 378, ISBN 0-443-05517-3, XP009563124-
OPPOSITION- Melgardt M. De Villiers, "10 Oral Conventional Solid Dosage Forms: Powders and Granules, Tablets, Lozenges, and Capsules", Melgardt M. De Villiers, Tapash K. Ghosh, Bhaskara R. Jasti, Theory and Practice of CONTEMPORARY PHARMACEUTICS, CRC Press, (20050101), pages 281 - 331, ISBN 0-415-28863-0, XP009563123-
OPPOSITION- Rowe, Raymond C., " Corn Starch and Pregelatinized Starch ", Handbook of Pharmaceutical Excipients,6th edition, (20090101), pages 200 - 201, ISBN 978-0-85369-792-3, XP009563126-
OPPOSITION- Rowe, Raymond C., " Cαrboxymethykellulose Sodium", Handbook of Pharmaceutical Excipients,6th edition, (20090101), pages 118 - 121, ISBN 978-0-85369-792-3, XP009563127-
OPPOSITION- Ursula Schöffling, "9.3 Hilfsstoffe", Ursula Schöffling, Schöffling, Ursula, Arzneiformenlehre: ein Lehrbuch der Galenik für Theorie und Praxis, DE , Dt. Apotheker-verlag , (20090101), pages 227 - 233, ISBN 978-3-7692-4093-1, XP009563115-
OPPOSITION- Okamoto Isamu, Iwama Eiji, Harada Taishi, Takayama Koichi, Nakanishi Yoichi, "Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer", ONCOTARGETS AND THERAPY, Dove Medical Press, doi:10.2147/OTT.S38868, ISSN 1178-6930, page 375, XP093307639

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents